Cargando…
A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model
BACKGROUND: The global burden of hepatitis B virus (HBV) infection in terms of morbidity and mortality is immense. Novel treatments that can induce a protective immune response are urgently needed to effectively control the HBV epidemic and eventually eradicate chronic HBV infection. METHODS: We des...
Autores principales: | Hu, Yunlong, Tang, Li, Zhu, Zhengyu, Meng, He, Chen, Tingting, Zhao, Sheng, Jin, Zhenchao, Wang, Zhulin, Jin, Guangyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055022/ https://www.ncbi.nlm.nih.gov/pubmed/32131853 http://dx.doi.org/10.1186/s12967-020-02275-2 |
Ejemplares similares
-
Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012) -
Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011) -
Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023) -
The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023) -
Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients
por: Liu, Xin, et al.
Publicado: (2023)